ATXS - Astria Therapeutics, Inc.
IEX Last Trade
9.25
-0.265 -2.865%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:30:22 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$9.52
-0.27
-2.79%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-0.21%
1 Month
-4.60%
3 Months
-10.00%
6 Months
5.76%
1 Year
40.50%
2 Year
-35.32%
Key data
Stock price
$9.25
DAY RANGE
N/A - N/A
52 WEEK RANGE
$7.44 - $16.90
52 WEEK CHANGE
$21.37
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Jill C. Milne
Region: US
Website: astriatx.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: astriatx.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema.
Recent news